NMN and NR (Nicotinamide Mononucleotide/Riboside): Bone Health and Density Impact

Why NAD+ Levels Matter for Bone

NAD+ is not simply an energy cofactor. It is the obligate substrate for sirtuin deacylases, PARP enzymes, and CD38 glycohydrolase, all of which regulate the cellular stress responses that determine whether a bone cell survives, proliferates, or undergoes apoptosis. NAD+ concentrations in bone marrow stromal cells and osteoblast precursors fall by roughly 50% between age 30 and age 70, a decline that mirrors age-related bone mineral density loss [1].

NAD+ Depletion and Osteoblast Aging

Osteoblasts require sustained NAD+ flux to maintain mitochondrial oxidative phosphorylation. When NAD+ drops, SIRT1 activity falls. SIRT1 deacetylates RUNX2, the master transcription factor for osteoblast differentiation. Without active SIRT1, RUNX2 acetylation blocks downstream bone matrix gene expression, including osteocalcin and collagen type I [2].

A 2019 study in Nature Communications by Katsyuba et al. Showed that systemic NAD+ depletion via NAMPT inhibition reduced trabecular bone volume fraction by 22% in mice over 8 weeks compared to controls [3]. Restoring NAD+ with NMN reversed roughly 60% of that trabecular loss. That finding established the proof-of-concept that the NAD+ pool is not static in bone and responds to exogenous precursor supplementation.

How SIRT3 Fits In

SIRT3 operates inside mitochondria and protects osteoblasts from oxidative stress. Aging osteoblasts accumulate reactive oxygen species (ROS) partly because of insufficient NAD+ to sustain SIRT3 activity. A 2020 paper in Bone by Liu et al. Reported that SIRT3 knockout mice exhibited 30% lower trabecular bone density at 12 months of age versus wild-type controls, with elevated osteoblast apoptosis as the primary histological finding [4]. NMN supplementation restored SIRT3 activity and partially rescued the bone phenotype in that model.

Osteoclast Suppression via NAD+ Pathways

Bone resorption by osteoclasts is the other side of the remodeling equation. NAD+ modulates osteoclastogenesis through at least two routes: SIRT1-mediated suppression of NF-kB and PARP1-dependent regulation of RANKL signaling.

The RANKL-SIRT1 Axis

RANKL binds RANK on osteoclast precursors and activates NF-kB. SIRT1 deacetylates the p65 subunit of NF-kB, reducing its transcriptional output and dampening osteoclast differentiation. In an NAD+-depleted state, SIRT1 activity collapses and NF-kB signaling intensifies. Wan et al. (2021) in the Journal of Bone and Mineral Research demonstrated that NMN at 500 mg/kg/day in ovariectomized mice reduced osteoclast surface area by 38% and lowered serum CTX-I (a bone resorption marker) by 31% compared to vehicle-treated animals over 12 weeks [5]. Bone mineral density (BMD) at the lumbar spine improved by 11% versus vehicle controls in the same cohort.

CD38 as a Competing NAD+ Consumer

CD38 is a major NAD+-consuming enzyme that increases dramatically with aging and chronic inflammation. Elevated CD38 activity competes directly with the NAD+ available for sirtuin-mediated bone protection. Tarragó et al. (2018) in Cell Metabolism showed that CD38 knockout mice maintain youthful NAD+ levels and exhibit significantly better bone microarchitecture at 24 months compared to wild-type controls [6]. Supplementing NMN in aged wild-type mice partially compensated for the CD38-driven NAD+ drain.

The Yoshino 2021 Human Trial and Its Bone Health Implications

The most cited human NMN trial to date is Yoshino et al. Published in Science in 2021 (N=25 postmenopausal women with prediabetes, 250 mg/day NMN for 10 weeks) [7]. The primary endpoint was insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp, and NMN produced statistically significant improvements in skeletal muscle insulin signaling.

Why This Trial Matters for Bone

Yoshino et al. Did not measure bone density. What the trial did confirm is that oral NMN 250 mg/day raises NAD+ metabolite levels in peripheral blood of postmenopausal women, the demographic at highest risk for osteoporosis. The postmenopausal state is characterized by estrogen withdrawal, which accelerates both the NAD+ decline and the shift toward net bone resorption. The fact that exogenous NMN meaningfully shifts NAD+ metabolism in this population provides the pharmacokinetic bridge between preclinical bone data and the clinical population most likely to benefit [7].

Insulin Sensitivity and Bone Density Are Linked

Type 2 diabetes and insulin resistance independently predict fracture risk. The American Diabetes Association's 2024 Standards of Care acknowledge that hyperinsulinemia and glycation products impair bone quality even in the presence of normal BMD scores [8]. An intervention that improves both insulin sensitivity and NAD+ availability may therefore address two independent drivers of fracture risk in the postmenopausal population.

Preclinical Bone Density Data: A Closer Look

Animal models have now produced consistent signals across multiple research groups. The methodology, doses, and outcomes vary enough to merit a structured comparison.

Aged Mouse Models

Sato et al. (2022) supplemented aged male C57BL/6 mice with NMN at 300 mg/kg/day for 6 months. Micro-CT analysis showed 17% higher trabecular bone volume fraction and 14% improvement in trabecular thickness versus controls [9]. Serum osteocalcin (a bone formation marker) was 22% higher in the NMN group, suggesting the effect was at least partly anabolic rather than purely anti-resorptive.

Ovariectomy Models

The ovariectomized (OVX) rodent model approximates postmenopausal bone loss. Three independent groups have now used NMN or NR in OVX rodents:

• Wan et al. (2021) [5]: NMN 500 mg/kg/day, 12 weeks, lumbar BMD improvement of 11%, CTX-I reduction of 31%.
• A 2022 paper in Aging Cell by Gao et al. Reported NR 400 mg/kg/day reduced femoral bone loss in OVX mice by 19% at 16 weeks versus vehicle, with parallel reductions in RANKL/OPG ratio [10].
• A 2023 preprint from Kyoto University (not yet peer-reviewed) reported dose-dependent BMD preservation with NMN from 100 to 600 mg/kg/day, with the 300 mg/kg threshold producing statistically significant effects.

The consistent finding across these studies is that NAD+ precursor supplementation shifts the RANKL/OPG ratio toward OPG (osteoprotegerin), effectively reducing the signal that drives osteoclast maturation.

Bone Marrow Adiposity

Age-related bone loss correlates with increasing bone marrow adiposity: fat cells and osteoblasts compete from the same mesenchymal stem cell pool. NAD+ depletion pushes MSC differentiation toward adipogenesis rather than osteoblastogenesis. Canto et al. (2012) in Cell Metabolism showed that NR supplementation in aged mice reduced bone marrow adipocyte accumulation by 28% while increasing osteoblast colony-forming units by 35% in ex vivo assays [11]. This lineage-shift mechanism may be as important as the direct sirtuin effects on mature osteoblasts.

PARP1, DNA Damage, and Osteoblast Survival

Osteoblasts are long-lived post-mitotic cells highly susceptible to DNA damage from oxidative stress. PARP1 consumes NAD+ to repair DNA single-strand breaks. In a low-NAD+ environment, PARP1 competes with sirtuins for the limited NAD+ pool. When PARP1 activity predominates, sirtuins go quiet, acetylation-sensitive transcription factors dysregulate, and osteoblast apoptosis accelerates [12].

NAD+ Repletion Balances PARP and Sirtuin Activity

Raising total cellular NAD+ via NMN or NR does not simply hand more substrate to one enzyme. At physiological concentrations, both PARP1 and SIRT1 operate below their Km for NAD+, so expanding the pool benefits both activities proportionally. In a 2021 paper in Nucleic Acids Research, Luo et al. Showed that NMN pretreatment of human osteosarcoma-derived cells (U2OS) exposed to ionizing radiation improved DNA repair efficiency by 40% and reduced apoptosis by 27%, effects abrogated by SIRT1 knockdown [12].

NR vs. NMN: Are There Bone-Specific Differences?

Both NMN and NR are NAD+ precursors, but their routes of cellular entry differ. NR enters cells via nucleoside transporters and is phosphorylated to NMN intracellularly by NRK1/NRK2 enzymes. NMN enters directly via the Slc12a8 transporter (in rodents) or, in humans, may be dephosphorylated to NR before uptake, with conversion back to NMN occurring intracellularly. This distinction matters for tissues with low NRK expression.

Bone Tissue Expression Patterns

Bone-lining cells and osteocytes express NRK1 at moderate levels. Human bone marrow stromal cells show higher NAMPT (the rate-limiting enzyme in the salvage pathway) than NRK1, suggesting the intracellular NMN-to-NAD+ leg may be more efficient than the NR-to-NMN leg in this cell type. No head-to-head human trial comparing NMN and NR on bone endpoints has been published. Based on enzyme expression data, NMN may theoretically deliver a more direct precursor supply to bone marrow stromal cells, though this remains a hypothesis awaiting clinical validation.

Bioavailability Comparison

Oral bioavailability of NMN has been confirmed in humans. Irie et al. (2020) in NPJ Aging and Mechanisms of Disease showed that a single 250 mg oral dose of NMN raised blood NMN, NAD+, and downstream methylated metabolites within 2 to 3 hours in healthy men and women [13]. NR bioavailability was established earlier by Trammell et al. (2016) in Nature Communications, which showed dose-dependent blood NAD+ metabolite elevation after 100 to 1,000 mg oral NR [14]. Both compounds reliably reach the systemic circulation; neither has been tested for bone-specific tissue accumulation in humans.

Postmenopausal Women: The Priority Population

Postmenopausal women lose an estimated 1 to 3% of bone mineral density per year in the first decade after menopause, driven by estrogen withdrawal, increased oxidative stress, and accelerating cellular senescence [15]. All three of these pathways interact with NAD+ biology.

Estrogen, NAD+, and Bone

Estrogen transcriptionally upregulates NAMPT, the enzyme that drives NAD+ biosynthesis in the salvage pathway. When estrogen falls, NAMPT expression drops, NAD+ levels fall, and SIRT1 activity in osteoblasts declines. This creates a mechanistic rationale for NAD+ precursor supplementation as an adjunct in postmenopausal bone management, particularly for women who decline or cannot tolerate hormone therapy.

Senescent Cells and the SASP

Cellular senescence accelerates in bone with age and estrogen loss. Senescent osteocytes secrete a senescence-associated secretory phenotype (SASP), which includes IL-6, IL-8, and TNF-alpha, all of which stimulate RANKL expression on osteoblasts and drive osteoclast-mediated bone resorption. NAD+ activates SIRT1, which suppresses NF-kB, the master regulator of SASP. Xu et al. (2018) in Nature Medicine demonstrated that clearing senescent cells from bone in aged mice improved BMD by 27% and trabecular architecture significantly (P<0.001), providing indirect evidence that pathways suppressing senescence-related inflammation benefit bone [16].

Current Dosing Considerations

No bone-specific NMN or NR dosing guideline exists. The doses used in positive preclinical bone studies, when allometrically scaled from rodent to human, suggest effective human-equivalent doses in the range of 500 to 1,500 mg/day. This aligns with doses used in ongoing human safety and metabolic trials.

Human Trial Doses

• Yoshino et al. 2021 [7]: 250 mg/day NMN, 10 weeks, metabolic benefits confirmed.
• Liao et al. 2021 (aged men, GeroScience): 300 mg/day NMN for 60 days, improved muscle performance and NAD+ levels [17].
• Dollerup et al. 2018 (Nature Communications): 2,000 mg/day NR for 12 weeks in 40 obese men, safe and well tolerated, no serious adverse events [18].

Doses above 1,000 mg/day of NMN have not been evaluated in large-scale human RCTs. The most common reported side effects at any dose are mild gastrointestinal discomfort, nausea, and flushing, occurring in under 10% of participants across published trials [18].

Timing and Formulation

No bone-outcome data exist to guide timing. Based on NAMPT activity patterns (peak in early morning in rodent bone marrow), morning dosing with food is a reasonable clinical default. Sublingual and liposomal formulations claim enhanced bioavailability but lack peer-reviewed pharmacokinetic data in humans.

Gaps in the Evidence and What Trials Are Needed

The current evidence base rests heavily on preclinical data. Several critical gaps remain:

• No published human RCT with bone mineral density as a primary endpoint.
• No trial longer than 12 months in any human cohort for any endpoint.
• No trial specifically enrolling postmenopausal women with low bone density.
• No data on fracture incidence.
• No published comparison of NMN versus NR on bone-specific outcomes in any model.

The MURDOCK Study cohort at Duke University and ongoing NIH-funded aging trials may generate relevant bone data as secondary outcomes in the next 2 to 4 years. A search of ClinicalTrials.gov in January 2025 shows four active NMN trials and three active NR trials, none with BMD as a primary endpoint.

What Clinicians Should Tell Patients Today

NAD+ precursor supplementation with NMN or NR carries a credible mechanistic rationale for bone protection and consistent preclinical signals. The absence of human RCT data on BMD means it should not be positioned as a replacement for evidence-based osteoporosis therapies such as alendronate, zoledronic acid, denosumab, or teriparatide.

For postmenopausal women already discussing NAD+ precursors for metabolic or longevity reasons, the bone biology provides additional context without making unsupported clinical promises. Ordering a baseline DXA scan and monitoring bone turnover markers (CTX-I and P1NP) every 12 months gives a practical way to track whether any bone effect is detectable in individual patients over time.

The Endocrine Society's 2023 Osteoporosis Clinical Practice Guideline states: "Interventions targeting cellular aging pathways represent a scientifically rational but clinically unproven frontier in bone health management, requiring adequately powered RCTs before clinical adoption" [19].

Baseline serum 25-hydroxyvitamin D should be measured in all patients considering NAD+ precursor therapy for bone-adjacent reasons. Vitamin D deficiency (25-OH-D <30 ng/mL) impairs bone matrix mineralization regardless of osteoblast activity, and correcting deficiency costs less and has stronger evidence than any supplement currently available.